888 An integrative approach to optimize a synthetic EphA2/CD137 agonist: balancing potency, physiochemical properties, and pharmacokinetics to achieve robust anti-tumor activity

• Kristen Hurov,
• Johanna lahdenranta,
• Gemma Mudd,
• Punit Upadhyaya,
• Elizabeth Repash,
• Julia Kristensson,
• Kevin McDonnell,
• Philip Brandish,
• Nicholas Keen,
• Phil Jeffrey

Affiliations

Kristen Hurov

1 Bicycle Therapeutics, 4 Hartwell Place, Lexington, Massachusetts, USA

Johanna lahdenranta

1 Bicycle Therapeutics, 4 Hartwell Place, Lexington, Massachusetts, USA

Gemma Mudd

Bicycle Therapeutics, Babraham Research Campus, Cambridge, UK

Punit Upadhyaya

1 Bicycle Therapeutics, 4 Hartwell Place, Lexington, Massachusetts, USA

Elizabeth Repash

1 Bicycle Therapeutics, 4 Hartwell Place, Lexington, Massachusetts, USA

Julia Kristensson

2 Bicycle Therapeutics, B900 Building, Babraham Research Campus, Cambridge, UK

Kevin McDonnell

1 Bicycle Therapeutics, 4 Hartwell Place, Lexington, Massachusetts, USA

Philip Brandish

1 Bicycle Therapeutics, 4 Hartwell Place, Lexington, Massachusetts, USA

Nicholas Keen

1 Bicycle Therapeutics, 4 Hartwell Place, Lexington, Massachusetts, USA

Phil Jeffrey

2 Bicycle Therapeutics, B900 Building, Babraham Research Campus, Cambridge, UK